Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.

Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance

Open access
Martins, Filipe, Sofiya, Latifyan, Sykiotis, Gerasimos P., Lamine, Faiza, Maillard, Michel, Fraga, Montserrat, Shabafrouz, Keyvan, Ribi, Camillo, Cairoli, Anne, Guex-Crosier, Yan, Kuntzer, Thierry, Michielin, Olivier, Peters, Solange, Coukos, Georges, Spertini, Francois, Thompson, John A., Obeid, Michel · 2019 · Nature Reviews Clinical Oncology

Abstract

Immune-checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1) and anti-programmed cell death 1 ligand 1 (PD-L1) antibodies, are arguably the most important development in cancer therapy over the past decade. The indications for these agents continue to expand across malignancies and disease settings, thus reshaping many of the previous standard-of-care approaches and bringing new hope to patients. One of the costs of these advances is the emergence of a new spectrum of immune-related adverse events (irAEs), which are often distinctly different from the classical chemotherapy-related toxicities. Owing to the growing use of ICIs in oncology, clinicians will increasingly be confronted with common but also rare irAEs; hence, awareness needs to be raised regarding the clinical presentation, diagnosis and management of these toxicities. In this Review, we provide an overview of the various types of irAEs that have emerged to date. We discuss the epidemiology of these events and their kinetics, risk factors, subtypes and pathophysiology, as well as new insights regarding screening and surveillance strategies. We also highlight the most important aspects of the management of irAEs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41571-019-0218-0

Cites

172 of 172 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

2 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 172 references

Cited by

See all 2,314

Metadata

Authors
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., Kuntzer, T., Michielin, O., Peters, S., Coukos, G., Spertini, F., Thompson, J. A., & Obeid, M.
Affiliations
  • Centre Hospitalier Universitaire Vaudois (CH)
  • National Institutes of Health (US)
Venue
Nature Reviews Clinical Oncology
Published
2019-05-15
Volume
16
Issue
9
Pages
563-580
ISSN
  • 1759-4774 (ISSN-L)
  • 1759-4782
OpenAlex
W2945590213
Cited by
2,314
References
172
Citations by year
2026: 271 · 2025: 374 · 2024: 427 · 2023: 347 · 2022: 366 · 2021: 309 · 2020: 182 · 2019: 35
FWCI
21.27
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Reviews Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
  • Archive ouverte UNIGE (University of Geneva) (publishedVersion)
  • Infoscience (Ecole Polytechnique Fédérale de Lausanne) (submittedVersion, cc-by-nc-nd)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Funders
  • Fondation Leenaards
  • Schweizerische Akademie der Medizinischen Wissenschaften (#2017-407)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
immune checkpoint inhibitors, immune-related adverse events, CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors, immune-related pneumonitis, immune-related colitis, immune-related endocrinopathy, immune-related dermatitis, risk factors, pathophysiology
MeSH terms
Antineoplastic Agents, Immunological, Humans, Immunologic Factors, Immunotherapy, Neoplasms, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. https://app.cochat.ai/papers/10.1038/s41571-019-0218-0
The paper
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., Kuntzer, T., Michielin, O., Peters, S., Coukos, G., Spertini, F., Thompson, J. A., & Obeid, M. (2019). Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-019-0218-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.